01 (S)-(+)-METHAMPHETAMINE HYDROCHLORIDE (1)
02 2-CYANO-3, 12-DIOXOOLEANA-1, 9(11)-DIEN-28-OIC ACID (CDDO) (1)
03 3-O-LAUROYL-L-CARNITINE HYDROCHLORIDE (LLC) PRECLINICAL AND CLINICAL DATA (1)
04 CHARACTERIZATION OF AEDES ALBOPICTUS (C6/36) MOSQUITO CELL LINE (1)
05 COCAINE HYDROCHLORIDE INJECTABLES (1)
06 COOPERATIVE STUDY GROUPS OF CLINICAL STUDIES PANEL (1)
07 DARAPRIM (PYRIMETHAMINE) (1)
08 DIMETHYL SULFOXIDE (1)
09 DON (NORLEUCINE, 6-DIAZO-5-OXO-,L). (1)
10 DRUG DEVELOPMENT PROGRAM (1)
11 ELLIOTT'S B SOLUTION (1)
12 GONADOTROPIN RELEASING HORMONE (GNRH) (1)
13 HUMANIZED MIK-BETA-1 MONOCLONAL ANTIBODY (1)
14 LISTING ----DIV BIOLOGICS NOTICES (IND'S) (1)
15 LYMPHILIZED PRODUCT OF AMINOPTERIN (NSC 739), 50MG (1)
16 MARIJUANA (PRODUCT CODE 1000) (1)
17 METHAMPHETAMINE HYDROCHLORIDE, INJECTABLE 10MG/1ML, 5ML AMPOULES (1)
18 NSC321803 (1)
19 PALUDRINE (1)
20 PC-4 (SILICONE PHTHALOCYANINE) (1)
21 PENTAMIDINE ISETHIONATE (1)
22 PSEUDOMONAS EXOTOXIN (RECOMBINANT, NLYSPE38) CONJUGATED MURINE MAB (B3) TO B3 ANTIGEN AND RITUXIMAB [CHIMERIC MOAB (C2B8) (IDEC) TO CD20] (1)
23 PYROXAMIDE CMC AND PRECLINICAL PHARMACOLOGY AND TOXICOLOGY DATA (1)
24 RECOMBINANT HUMAN INTERLEUKIN-15 (RHIL-15) (1)
25 SANGIVAMYCIN HCL (NSC 143648) AS PREPARED BY THE FREDERICK CANCER RES. (1)
26 STATEMENT OF PERSONNEL FACILS AND CONTROLS FOR PROCESSING A NEW DRUG (1)
27 THYMIDINE (NSC21548) (1)
01 DIV OF THERAPEUTICS AND MEDICAL CONSEQUENCES (1)
02 DIVISION OF CANCER TREATMENT AND DIAGNOSIS (3)
03 NATIONAL CANCER INSTITUTE (8)
04 NATIONAL INSTITUTE ON DRUG ABUSE (1)
05 NATIONAL INSTITUTES HEALTH NATIONAL CANCER INSTITUTE (3)
06 NATIONAL INSTITUTES HEALTH NATIONAL INSTITUTE ALLERGY AND INFECTIOUS DISEASES (1)
07 NATIONAL INSTITUTES HEALTH NATIONAL INSTITUTE CHILD HEALTH AND HUMAN DEVELOPMENT (1)
08 NATIONAL INSTITUTES HEALTH NATIONAL INSTITUTE DRUG ABUSE (2)
09 NATIONAL INSTITUTES OF HEALTH CLINICAL CENTER (7)
01 U.S.A (27)
01 Active (5)
02 Inactive (22)
01 Blank (27)